Table 1 Baseline characteristics of the study population
Variables | csDMARDs (n=43) | TNFi (n=64) | P-value |
|---|---|---|---|
Cardiovascular disease risk factors | |||
 Age, median years (IQR) | 58.6 (53.0, 66.0) | 58.1 (49.3, 67.0) | 0.839 |
 Female sex | 33 (76.7) | 54 (84.4) | 0.321 |
 Obesity | 5 (11.6) | 7 (10.9) | 0.999 |
 Hypertension | 19 (44.2) | 30 (46.9) | 0.784 |
 Anti-hypertensive drug | 17 (39.5) | 28 (43.8) | 0.784 |
 Smoking status, ever | 18 (42.9) | 30 (46.9) | 0.684 |
 Dyslipidaemia | 30 (40.2) | 34 (59.8) | 0.085 |
 Current statin use | 13 (34.2) | 10 (15.9) | 0.033 |
 Diabetes mellitus | 3 (7.0) | 3 (4.7) | 0.676 |
 Anti-diabetic medication | 1 (2.3) | 1 (1.5) | 0.999 |
 CVD risk factors, median (IQR) | 2 (1, 3) | 2 (1, 3) | 0.199 |
Rheumatoid arthritis characteristics and treatment | |||
 RF and/or ACPA positive | 28 (65.1) | 33 (51.6) | 0.165 |
 Disease duration, median years (IQR) | 14.1 (11.5) | 15.4 (10.5) | 0.538 |
 Methotrexate | 38 (88.4) | 52 (81.3) | 0.192 |
 Leflunomide | 5 (17.9) | 12 (19.0) | 0.999 |
 Hydroxychloroquine | 9 (31.0) | 5 (7.8) | 0.009 |
 Prednisone > 5 mg daily | 7 (7.7) | 5 (5.5) | 0.823 |
 NSAIDs | 6 (20.7) | 22 (34.4) | 0.227 |